Giulio Sartori
Lugano, TI, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma.
Journal: British journal of haematology
Published: February 04, 2026
Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma.
Journal: Cancer medicine
Published: October 11, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
Journal: bioRxiv : the preprint server for biology
Published: July 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
Journal: Blood
Published: May 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
Journal: Blood
Published: May 14, 2025
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies.
Journal: Haematologica
Published: December 12, 2024
FLI1 Induces Plaque Psoriasis and Its Inhibition Attenuates Disease Progression.
Journal: Journal of inflammation research
Published: October 22, 2024
Chemosensor receptors are lipid-detecting regulators of macrophage function in cancer.
Journal: Nature immunology
Published: March 21, 2024
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
Journal: British journal of haematology
Published: July 10, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
Journal: Molecular cancer therapeutics
Published: February 02, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms.
Journal: bioRxiv : the preprint server for biology
Published: January 30, 2023
Last Updated: 09/26/2026